
NACLC (IASLC)
The IASLC 2022 North America Conference on Lung Cancer will take place September 23-25, 2022 at the Chicago Marriott Downtown Magnificent Mile. After last year’s
The IASLC 2022 North America Conference on Lung Cancer will take place September 23-25, 2022 at the Chicago Marriott Downtown Magnificent Mile. After last year’s
Date/Time: September 30 from 5.30PM – 9.30PM EDT Objectives: Discuss relevant updates for common cancers to include Lung, GI, GYN, Breast, GU, Neuro, Immunotherapy and an overview
Webinar Presented by Dr Maher Albitar, MD / Dr Martin Gutierrez, MD / Nikki Martin September 29, 2021 12:00 PM EST Course Description: This webinar will
GTC is honored to participate in a webinar hosted by RUNX1 and the MDS Foundation: Get Free Access to Genetic Testing for Underserved MDS and Hematologic
Presented by Dr. James McCloskey and Dr. Maher Albitar This Webinar will focus of the clinical relevance of distinguishing myelodysplastic syndrome from acute myeloid leukemia. It
SAN FRANCISCO (PRWEB) JUNE 14, 2022. HALO Diagnostics, a precision diagnostics leader, has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served. This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment.
Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of
Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO)
IRVINE, California, May 25, 2022 – Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as